secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001477932-26-001830
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx FY2025 revenue up 40% to $1.7M; net loss down 14%
------------------------------------------------------------

- Full-year revenue $1.7M (+40% YoY); Q4 revenue growth 133% vs prior year.
- Operating expenses down $4.8M (17%); net cash used in ops $19.7M (-24%).
- Received first order for Nu.Q Cancer assays for lung cancer clinical certification.
- Nu.Q NETs assay included in French government-backed sepsis study (~$7.3M).
- Subsequent to year end: raised $5.4M ATM equity, $1.9M convertible note, $1.0M non-dilutive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793226001830/0001477932-26-001830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793226001830/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-001830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer